Skip to main content
Market snapshot: . Prices may have changed since this snapshot.
Events
GroupKALSHI
When will Beam Therapeutics submit a BLA for Risto-cel?
When will Beam Therapeutics submit a BLA for Risto-cel?
Reported volume
K 11.2K contracts
Events
1
Markets
3

Current odds

Snapshot from

As of Nov 22, 2026, 3:00 PM UTC, the highest-priced outcome on Kalshi is before April 2027 at 83.5%.

Kalshi

  1. before April 202783.5%
  2. before 202745%
  3. before December8%

Yes prices. They are not order quotes; check each platform's rules, fees and live prices before trading.

AI Analysis

Trader mode: Market mechanics, assumptions and risks

K 11.2K contracts

Reported volume ยท provider units

3

Saved contracts

0

Same-question pairs

Source snapshot: Nov 22, 2026, 3:00 PM UTC

This analysis was written from an earlier market snapshot, so its prices may be older than the odds above.

Snapshot observed Nov 11, 2026, 3:00 PM UTC. This analysis describes that snapshot and is not a live news update.

What the contract measures

The supplied Kalshi event asks when Beam Therapeutics will submit a biologics license application to the FDA for ristoglogene autogetemcel (risto-cel) [1]. The event excerpt says that if the submission occurs "before X 1, 2027, then the market resolves to Yes" [1]. The three saved markets use different deadline wording in their titles: "before April 2027," "before 2027," and "before December" [1]. Their listed end times are 2027-04-08 14:00 UTC, 2027-01-08 15:00 UTC, and 2026-12-08 15:00 UTC [1]. These are listed close times, not announced event dates. The excerpt also states an early close condition if the event occurs, and the event-level listed end time is not supplied [1].

Reading the snapshot

The snapshot was observed at 15:00:06 UTC on 11 November 2026 and retrieved at 16:53:08 UTC the same day [1]. For the April 2027 market, the Yes price was 0.855 and the No price was 0.145 [1]. For the 2027 market, Yes was 0.555 and No was 0.445 [1]. For the December market, Yes was 0.135 and No was 0.865 [1].

These are snapshot prices, not executable quotes or verified probabilities. Each market has a different deadline, so the three prices answer different questions. They should not be averaged or combined into one forecast. The sample does not explain why the prices are at these levels. Volume and trader counts are not supplied, so the prices cannot be read as liquidity or agreement among traders.

What remains uncertain

The coverage record shows all 3 saved markets included, with partialSample set to false [1]. The sample warning adds that this does not establish that the provider lists every possible real-world outcome [1].

The source is an official Kalshi record with provider status active [1]. No information about submission timing, FDA review, or recent developments is supplied, so this snapshot cannot speak to them. The event text reads "before X 1, 2027," which does not match the specific market titles. Check the exact deadline on the provider page before comparing contracts.

Price differences between these contracts reflect different deadlines and are not an arbitrage signal. The prices describe one retrieved snapshot and may have changed since then.

References

  1. Kalshi: When will Beam Therapeutics submit a BLA for Risto-cel?. Provider data observed Nov 11, 2026, 3:00 PM UTC.

AI-generated analysis based on market data. Not financial advice.

Saved Nov 11, 2026 UTC

This article was written from an earlier market snapshot and may be out of date. Use the dated market data and provider rules above for current information.

Overview

This contract asks whether Beam Therapeutics Inc. will submit a biologics license application (BLA) for ristoglogene autogetemcel, also called risto-cel, to the U.S. Food and Drug Administration. The contract rule states that if the submission happens before the stated cutoff, the market resolves to Yes [1]. The rule also includes an early close condition: the market closes and expires early if the event occurs [1]. The source lists three related markets under this one event, each with a different cutoff. One asks about a submission before December 8, 2026, another before January 8, 2027, and the third before April 8, 2027, as shown by the listed end dates [1]. The cutoff wording in the rule text is partly garbled in the retrieved copy, so the market titles and listed end dates are the clearer statements of each deadline. The source does not identify a scheduled submission date, and a cutoff date in contract rules is not an announcement that a submission will occur on that date [1]. Each market shows Yes and No prices. In the snapshot recorded at 15:00 UTC on November 11, 2026, the Yes price was 0.855 for the April 2027 cutoff, 0.555 for the January 2027 cutoff, and 0.135 for the December 2026 cutoff [1]. These figures are observed prices at that time, not executable quotes or verified probabilities. Because the three markets have different deadlines, their differing prices reflect different questions and do not by themselves indicate a mispricing.

Why It Matters

The contract measures whether a specific regulatory filing, a BLA for risto-cel, is submitted to the FDA before a stated cutoff [1]. Its value depends on the timing of that submission. The three linked markets allow the same question to be framed with three different deadlines: December 8, 2026, January 8, 2027, and April 8, 2027 [1]. The market prices shown in the snapshot express the traded price of each Yes outcome at one moment and are not a forecast or a guarantee of what will happen [1].

Snapshot context

The latest published provider snapshot for this topic was observed on 2026-11-11 at 15:00 UTC. It contains listings from Kalshi. Market descriptions and listed closing times define the contracts; they do not establish that the real-world outcome has occurred. This article does not include a separately verified news update. [1]

Frequently Asked Questions

What event makes the contract resolve to Yes?

The rule states that if Beam Therapeutics Inc. submits a BLA for ristoglogene autogetemcel, risto-cel, to the FDA before the stated cutoff, the market resolves to Yes [1].

Does the early close condition matter?

The source says the market will close and expire early if the event occurs [1]. This means the contract can end before its listed end date once the submission happens.

Are the three markets the same question?

They share one event and the same underlying submission, but each market uses a different cutoff: before December 2026, before 2027, and before April 2027 [1]. Their prices should be read separately for each cutoff.

Do the prices show the chance that the submission will happen?

The prices are snapshots from one observation time and are not executable quotes or verified probabilities [1]. They reflect market trading at that moment, not confirmed information about the company's plans.

Was this helpful?
Saved Nov 11, 2026 UTC

AI-written background. References identify the evidence used; Wikipedia links under Learn More are additional reading. Prices and provider rules are dated snapshots. This is not financial advice.

Prices are catalog snapshots and may have changed. Check each market's rules and observation time.

KalshiHealth
When will Compass Pathways submit a NDA for COMP360 psilocybin?

When will Compass Pathways submit a NDA for COMP360 psilocybin?

K 17.8K contracts
When will COMPASS Pathways plc submit a NDA for COMP360 psilocybin to the FDA? (before April 2027)Yes 98.5%
When will COMPASS Pathways plc submit a NDA for COMP360 psilocybin to the FDA? (before 2027)Yes 98%
When will COMPASS Pathways plc submit a NDA for COMP360 psilocybin to the FDA? (before December)Yes 96%
3 mktsNext deadline Dec 1, 2026 UTC
KalshiFinancials
FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)

K 4.2K contracts
What will the FDA's decision be on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026?Yes 88.5%
1 mktNext deadline Jan 1, 2027 UTC
KalshiFinancials
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

K 1.8K contracts
What will the FDA's decision be on Saroglitazar by Zydus Therapeutics in 2026?Yes 75.5%
1 mktNext deadline Jan 1, 2027 UTC
KalshiFinancials
FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)

FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)

K 75.66 contracts
What will the FDA's decision be on Lorundrostat by Mineralys Therapeutics on or before December 22, 2026?Yes 83.5%
1 mktNext deadline Dec 23, 2026 UTC
KalshiFinancials
FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)

FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)

K 41.42 contracts
What will the FDA's decision be on Ralinepag by United Therapeutics on or before June 24, 2027?Yes 79.5%
1 mktNext deadline Jun 25, 2027 UTC
KalshiHealth
When will the FDA approve Intellia Therapeutics' lonvo-z?

When will the FDA approve Intellia Therapeutics' lonvo-z?

K 6.6K contracts
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)Yes 92.5%
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027)Yes 92%
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027)Yes 89%
3 mktsNext deadline Jul 1, 2027 UTC

Market Insights

Price gaps of 2 pp+

0

Same-question pairs

0

No outcomes on this page have been reviewed as the same question on both platforms yet.

Price differences do not establish arbitrage. Check each pair's review, current order prices, fees and settlement rules.

Trade This Market